• 한국임상약학회지
• /
• 제26권1호
• /
• pp.24-32
• /
• 2016

Objective: The visually impaired have limited access to health care services and related information, and thus, they can have serious hurdles against properly taking medications. Despite that it is important to improve self-care ability of the visually impaired for correct medication use, there have been few studies investigating their needs for health care services in Korea, particularly focusing on proper medication usage. This study is to explore safety-related issues regarding mediation usage among the visually impaired based on in-depth interview. We particularly focus on any obstacles for safe use of medicines including experience on medication-related adverse effects in order to provide preliminary evidence for policy measures to improve proper medication use among the visually impaired. Methods: Study sample was visually impaired individuals who resided in Seoul area and were registered in the National Association of Visually Impaired. The association helped the process of recruiting the study participants. In-depth interview for each study participants was conducted. Each interview was recorded and later converted into a written script to extract core contents for the analysis. Results: The study participants comprised of three women (42.9%) and four men (57.1%). One was in his 20's, and there were four participants in 30's and two in 40's. Fully impaired participants were majority (5 out of 7). Limitation to physical access to health care providers and health information were the key factors to hamper safe medication utilization among the study participants. Difficulty reading medication information and may take the wrong medication or incorrect doses of medication, resulting in serious consequences, including overdose or inadequate treatment of health problems. Visually impaired patients report increased anxiety related to medication management and must rely on others to obtain necessary drug information. Pharmacists have a unique opportunity to pursue accurate medication adherence in this special population. This article reviews literature illustrating how severe medication mismanagement can occur in the visually impaired elderly and presents resources and solutions for pharmacists to take a larger role in adherence management in this population. Conclusion: The visually impaired had difficulties reading medication information and identifying medicines, and took incorrect doses of medications. Public support for safe medication use and medication management among the visually impaired is necessary.

• 한국식품저장유통학회지
• /
• 제12권1호
• /
• pp.95-100
• /
• 2005

풋마늘의 이용성을 증대시키고 합리적인 소비를 촉진시키기 위해 풋마늘의 영양성분을 조사하였고, 풋마늘 분말을 첨가한 빵을 제조하여 관능검사 및 미생물학적 특성을 조사하였다. 동결건조하여 분쇄한 풋마늘 분말의 일반성분은 수분 $6.99\%$, 조단백질 $7.62\%$, 조지방은 $1.84\%$, 회분 $6.60\%$, 탄수화물이 $76.95\%$였고, 유리당은 glucose, fructose와 sucrose가 확인되었다. 무기성분은 K이 1,140 mg/100 g으로 가장 많았으며, Ca, P, Na의 함량이 높았다. 총아미노산과 유리 아미노산은 methionine, cystine, proline과 glutamic acid 등의 함량이 높게 나타났다. 풋마늘 분말을 0.5, $1.0\%$ 첨가하여 제조한 빵의 세균 성장이 대조구 보다 약 1일 정도 느렸으며, 관능검사 결과 $0.5\%$ 정도까지 풋마늘 분말을 첨가하여 제조한 빵의 텍스쳐는 대조구와 큰 차이가 없었다. 이러한 결과 풋마늘 분말을 빵에 $0.5\%$정도까지 첨가함에 따라 빵의 기능성은 향상시킬 뿐만 아니라 제품의 shelf-life 연장 효과를 가져올 것으로 보인다. 본 실험에서는 동결건조한 풋마늘을 빵에 다양한 수준으로 첨가하여 풋마늘 첨가빵의 개발가능성을 살펴보았다. 빵의 제조시 제조방법을 개선하고 표준화하여 우수한 품질의 풋마늘 첨가빵 개발한다면 풋마늘의 이용성을 높임과 동시에 기능성을 고려한 제품이 될 수 있다고 생각된다.

• 한국콘텐츠학회논문지
• /
• 제13권4호
• /
• pp.281-289
• /
• 2013

최근 국내 임상시험의 양적 증가와 더불어, 임상시험 자료를 효율적으로 관리할 수 있는 Electronic Data Capture(EDC) 시스템의 도입 요구가 증가하고 있다. 이에 따라 식품의약품안전청에서는 '임상시험 전자 자료 처리 및 관리를 위한 가이드라인'을 발표하였다. 이는 향후 국내 임상시험 전자 자료 관리에 관한 법률 제정을 위한 기초가 될 것으로 기대한다. 이 연구에서는 국내 임상시험 관련 기관인 병원과 임상시험 수탁기관(CRO), 그리고 제약회사에서의 EDC 시스템 이용 현황과 관계자들이 인식하는 가이드라인 및 전자 자료 표준의 중요성 및 적용 용이성과 이해도를 조사하였다. 국내 임상시험 관련 기관에서의 EDC 시스템 이용률은 77.6% 이었지만 EDC 시스템을 이용한 임상시험 건수는 5건 미만이 가장 많았다. EDC 시스템은 주로 약물동력학 시험을 하는 phase I과 임상효과와 안전성을 평가하는 phase II 임상시험에서 주로 이용되었고, 기관별로는 CRO의 이용률이 가장 높았다. 모든 집단에서 가이드라인의 중요성은 높게 인식하였으나, 적용 용이성 측면에서는 CRO에서 가장 높았다. 또한, 임상시험 전자 자료 표준의 중요성을 높게 인식하였고, 전자 자료 수집에 있어 표준의 필요성을 높게 인식하였다. 그러나 임상시험 전자 자료 국제표준인 Clinical Data Interchange Standard Consortium(CDISC)에 대한 이해도는 아직 낮은 수준이었다. 이 연구 결과는 국내 임상시험 전자화를 위한 기초자료로 활용될 수 있으며 임상시험 자료 표준에 관한 정책수립에도 활용될 수 있을 것이다.

• 대한화장품학회지
• /
• 제42권3호
• /
• pp.227-233
• /
• 2016

본 연구에서는 세토카 가지 정유의 주요 성분을 분석하고 이들의 항균, 항염 및 세포독성 실험을 진행하였다. 세토카는 제주도에서 널리 재배되고 있는 감귤류의 품종이다. 세토카 나무의 가지는 간벌 작업으로 인해 대부분 폐기되고 있고, 이러한 폐자원의 활용은 최근 많은 관심을 받고 있다. 정유 성분은 세토카 가지의 에탄올 추출물을 호호바오일로 처리하여 얻었다. 세토카 정유의 주요 성분은 ethyl linoleate (64.1%), ethyl palmitate(16.5%), neophytadiene (11.1%) 및 ${\beta}$-citronellol (5.1%)임을 확인하였다. 이들의 항균활성을 확인하기 위하여 피부 관련 미생물에 대한 paper disc 확산법을 실시한 결과 Staphylococcus aureus 및 Propionibacterium acnes에서 좋은 항균활성을 보였다. 또한 항염활성을 확인하기 위해 lipopolysaccharide(LPS)로 염증이 유도된 대식세포에서 nitric oxide (NO) 생성량을 측정한 결과 세토카 정유 성분은 농도의존적으로 NO 생성을 저해하였다. WST-1 분석법을 이용하여 세포독성을 측정한 결과 RAW 264.7 macrophage 및 HaCaT 각질형성세포에서 세포생존율이 무처리 대조군과 비슷한 결과를 보였다. 이러한 결과를 바탕으로 세토카 가지 정유는 세포독성이 없으면서 염증억제 및 항균효과가 있음을 확인하였으며, 이를 응용한 화장품소재로써의 개발이 가능할 것으로 여겨진다.

• Nutrition Research and Practice
• /
• 제11권1호
• /
• pp.3-10
• /
• 2017

BACKGROUND/OBJECTIVES: Sargassum horneri is an edible brown alga that grows in the subtidal zone as an annual species along the coasts of South Korea, China, and Japan. Recently, an extreme amount of S. horneri moved into the coasts of Jeju Island from the east coast of China, which made huge economic and environmental loss to the Jeju Island. Thus, utilization of this biomass becomes a big issue with the local authorities. Therefore, the present study was performed to evaluate the anti-inflammatory potential of crude polysaccharides (CPs) extracted from S. horneri China strain in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. MATERIALS/METHODS: CPs were precipitated from S. horneri digests prepared by enzyme assistant extraction using four food-grade enzymes (AMG, Celluclast, Viscozyme, and Alcalase). The production levels of nitric oxide (NO) and pro-inflammatory cytokines, including tumor necrosis factor (TNF)-${\alpha}$ and interleukin (IL)-$1{\beta}$ were measured by Griess assay and enzyme-linked immunosorbent assay, respectively. The levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), nuclear factor (NF)-${\kappa}B$, and mitogen-activated protein kinases (MAPKs) were measured by using western blot. The IR spectrums of the CPs were recorded using a fourier transform infrared spectroscopy (FT-IR) spectrometer. RESULTS: The polysaccharides from the Celluclast enzyme digest (CCP) showed the highest inhibition of NO production in LPS-stimulated RAW 264.7 cells ($IC_{50}$ value: $95.7{\mu}g/mL$). Also, CCP dose-dependently down-regulated the protein expression levels of iNOS and COX-2 as well as the production of inflammatory cytokines, including TNF-${\alpha}$ and IL-$1{\beta}$, compared to the only LPS-treated cells. In addition, CCP inhibited the activation of NF-${\kappa}B$ p50 and p65 and the phosphorylation of MAPKs, including p38 and extracellular signal-regulated kinase, in LPS-stimulated RAW 264.7 cells. Furthermore, FT-IR analysis showed that the FT-IR spectrum of CCP is similar to that of commercial fucoidan. CONCLUSIONS: Our results suggest that CCP has anti-inflammatory activities and is a potential candidate for the formulation of a functional food ingredient or/and drug to treat inflammatory diseases.

• 한국식품위생안전성학회지
• /
• 제35권6호
• /
• pp.607-617
• /
• 2020

인체 바이오모니터링(Human biomonitoring, HBM) 데이터는 뇨와 혈액 등 생체지표으로부터 환경유해물질의 측정을 통해 획득되며, 다양한 노출원과 경로로부터 노출되는 유해물질의 인체노출수준 및 건강영향과의 상관성을 파악하기 위해 매우 중요하다. 국내의 경우 식품의약품안전처를 비롯한 국가기관의 다양한 HBM 프로그램을 통하여 HBM 데이터가 생산되고 있다. 그러나, 목적, 시기, 연구자 및 측정 장비의 차이에 의하여 서로 다른 형식에 따라 생산되다 보니, 데이터의 호환성의 문제로 인하여 특정 HBM 데이터를 신속하게 조회해야 하거나 인구집단별 시간적 추이분석 내지는 다른 국가의 자료와 비교에 난점을 가지고 있다. 따라서, 본 연구에서는 HBM 데이터를 체계적으로 데이터베이스(Database, DB)화하고 활용성을 증진하게 시킬 목적으로 지식 모델링을 실시하였다. 지식 모델링은 HBM 데이터의 생산되는 변수들을 그룹화하고 관계를 분석하여 2차원 구조의 개체 및 집합론에 기초한 방법론인 관계형 데이터 모델링 기법을 활용하여 실시하였다. 지식모델은 조사대상자를 인구집단으로 중심으로 설문자료, 측정자료, 노출 평가자료 개체로 구성하고 그 안에 속성들을 정의하고, 개체간에 관계를 설정하는 방식으로 구성하였다. 또한, 도출된 지식 모델을 기반으로 식품의약품안전처에서 2006년-2018년까지 수행한 HBM의 원시데이터를 수집, 정제 및 정규화하여 통합 DB를 구축하였다. 이와 같이 통합된 HBM-DB는 개별 자료원 내지는 특정 자료원들을 선택하여 기간별 농도 수준에 대한 통계분석은 물론, 다양한 검색조건을 통하여 데이터 추출을 할 수 있는 구조로 구축하였다. 본 HBM-DB는 관계형 DB모델로 구축되어 지속적인 대용량 DB 축적이나 HBM 데이터 해석을 위한 도구로써 효율적으로 수행할 수 있을 것으로 생각된다.

• 한국임상약학회지
• /
• 제32권3호
• /
• pp.185-190
• /
• 2022

Background: Denosumab (Prolia®) is administered every 6 months for osteoporosis treatment. Co-administration of calcium and vitamin D is required to minimize hypocalcemia risk. We evaluated clinical outcomes based on the administration interval of denosumab and co-prescription with calcium-vitamin D combination products. Methods: A retrospective study was conducted using electronic medical records from 668 patients who started denosumab therapy between January 1 and December 31, 2018, at Seoul National University Bundang Hospital. Clinical outcomes, as measured by changes in T-score, were evaluated by the intervals and concurrent prescriptions with calcium-vitamin D combination products. Results: Of the 668 patients, 333 patients met the eligibility criteria. These patients were divided into two groups based on appropriateness of the administration interval: "Appropriate" (304 patients, 91.3%) and "Inappropriate" (29 patients, 8.3%). T-score changes were significantly higher in the "Appropriate" than in the "Inappropriate" group (0.30±0.44 vs. 0.13±0.37, p=0.048). At the beginning of the treatment, 221 patients (66.4%) were prescribed calcium-vitamin D combination products, but the changes in T-scores were not significantly different by the prescription status of the product (0.29±0.46 vs. 0.28±0.38, p=0.919). Conclusion: T-scores were significantly improved in patients with appropriate administration intervals. No significant changes in T-scores were observed by the prescription status with calcium-vitamin D combination products. For optimal treatment outcomes, prescribers should encourage adherence to the approved prescription information on dosage and administration, and pharmacists should provide medication counseling for patients.

• 지역과문화
• /
• 제7권4호
• /
• pp.49-68
• /
• 2020

현대인의 정신질환에 대한 보완의학 연구는 학문적 분야별로 이루어져 왔다. 심리치료, 미술치료, 문학치료, 무용치료 등이 그 중 하나지만 이러한 비통합적 연구를 현실에 적용하기는 극히 제한적이다. 약물치료 후 보완책을 모색하는 의료계와의 협업도 문제고, 이를 정책적으로 제도화하기는 더욱 어렵다. 이에 본 연구는 대부분의 치료 프로그램이 중시하는 공간의 가치를 연구해 공간 중심의 치료 패러다임으로의 전환을 제언하였다. 독일에서 발달해 국내에 유입된 통합문학치료학의 이론을 기저로 고찰하고 테트라시스템을 우리의 문화유산이도 한 고택 공간에 대입해 적용했다. 그리고 고택 공간의 특성을 치료 프로그램화 하는 방안을 샘플로 제시해 보았다. 안동시의 권성백 고택을 대표적인 공간으로 보고 분석해 보았다. 유사 사례로서 힐리언스 선마을, 독일의 크나이프 마을, 봉은사 템플스테이를 살펴보고 공간의 활용 실태를 파악하였다. 이에 고택 공간들을 테트라시스템으로 분석해 걷기, 시 쓰기, 풍욕, 편지 쓰기 등의 공간치료 프로그램을 제시하였다. 이는 공간의 장소화와 장소성을 프로그램에 접목하는 시초의 연구로서 의미가 크다 할 것이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7367-7369
• /
• 2013

Background: Inoperable and metastatic hepatocellular carcinoma (HCC) is associated with a poor prognosis and low chemotherapeutic efficiency. Sorafenib is an oral multi-kinase inhibitor exerting its effects via the RAF/MEK/ERK pathway, vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor beta (PDGFR-${\beta}$) tyrosine kinases. Randomized studies have shown a significant contribution of sorafenib to life expectancy and quality of life of cancer patients. The aim of the present study is to evaluate the efficacy and side effects of sorafenib therapy in Turkey. Materials and Methods: Data for 103 patients (82 males, 21 females) receiving sorafenib therapy in 13 centers from February 2008 to December 2012 were evaluated. Median age was 61 years and median ECOG performance status was 1 (range: 0-2). 60 patients (58%) had hepatitis B, 15 patients (15%) had hepatitis C infection and 12 patients (12%) had a history of alcohol consumption. All of the patients had Child scores meeting the utilization permit of the drug in our country (Child A). Results: A total of 571 cycles of sorafenib therapy were administered with a median of four per patient. Among the evaluable cases, there was partial response in 15 (15%), stable disease in 52 (50%), and progressive disease in 36 (35%). Median progression-free survival was 18 weeks and median overall survival was 48 weeks. The dose was reduced only in 6 patients and discontinued in 2 patients due to grade 3-4 toxicity, 18 patients (17%) suffering hand-foot syndrome, 7 (7%) diarrhea, and 2 (2%) vomiting. Conclusions: This retrospective study demonstrated better efficacy of sorafenib therapy in patients with advanced HCC compared to the literature while progression-free survival and overall survival findings were comparable. The side effect rates indicate that the drug was tolerated well. In conclusion, among the available treatment options, sorafenib is an efficient and tolerable agent in patients with inoperable or metastatic HCC.

• 대한본초학회지
• /
• 제27권2호
• /
• pp.1-16
• /
• 2012

Objective : To investigate the current status of prescription drugs in Oriental medical institutes and to draw up a future plan for the revitalization of Oriental medical health insurance, this survey has been performed. Method : The survey has been made with 321 doctors working at Oriental medical institutes in Daegu and Kyungbuk areas for a period of 3 month from June 1, 2010 until September 1, 2010. Result : 1. When it comes to the current status of the use of herbal drugs in Oriental Health insurance, most of doctors surveyed prescribe insurance drugs, and they prescribe insurance drugs to patients, who are less than 20% of total patients visiting their clinics. 2. The awareness of Herbal Health Care Drugs is investigated. When it comes to the understanding of the difference between insurance drugs(powder type drugs) and granular type drugs, doctors admit that they differ only in one aspect, whether or not their being covered by health insurance. Based on the survey results on the understanding of insurance coverage of granular type drugs, doctors, even though they long for granular type drugs to be accepted as insurance drugs, are worrying whether the number of outpatients might dwindle due to increased insurance co-payments. They also point out that the biggest obstacles in the expansion of the granular type drugs as insurance drugs are the lack of understanding of the government and the objection of the Health Insurance Review and Assesment service (HIRA) for fear of increased insurance claims. 3. Upon investigation on Oriental medicine doctors' understandings of herbal pharmaceutical industry, it is found that doctors' responses on pharmaceutical industry are not all positive ones('new product development and neglect of R&D infrastructure' and 'smallness of industry'). When it is investigated what area needs the greatest improvement in herbal pharmaceutical industry, 'securing sufficient capital, good manufacturing, and strengthening quality control', is the highest. 4. When it is asked what are the most needed in order to improve herbal health insurance medicine, responses such as 'the increase in the accessibility to and the utilization of Oriental medical clinics through the diversification of the means of prescriptions', 'the improvement of insurance benefits(cap adjustments)', 'increase the proportion of high quality medicinal plants', 'the ceiling of co-payments(deductible) at 20,000 won or more', 'expansion of the choices of formulations', 'formulational expansions of tablets and pills', and finally 'admittance and expansion of granular type drug as insurance drug' are the highest. 5. Upon investigating the general characteristics of the current status of the usage of Oriental health care herbal drugs, the followings are observed. First, the frequency of use of health insurance drugs by the doctors who use health insurance with general characteristics shows similar differences in case of total monthly sales amount (p<0.001), average number of daily patients (p<0.05). Secondly, as to the willingness of the expanded usage of insurance drugs, similar differences are observed in case of total monthly sales amount (p<0.05). 6. Upon investigating the general characteristics of the perception of Herbal health care drugs, the followings are observed. First, inspecting general characteristics and insurance claims due to increased co-payments(deductible amount) reveals similar differences in case of working period (p<0.01) and in case of total monthly sales amount (p <0.01). Secondly, inspecting general characteristics and the obstacles that hinder granular type drugs from being accepted as health care insurance drugs shows similar differences in case of working period (p<0.05). 7. Upon investigating the general characteristics of the understanding of Oriental Herbal pharmaceutical companies, the followings are observed. First, opinions on the general characteristics of pharmaceutical companies, when examined with variance analysis, shows similar differences in case of total monthly sales amount (p<0.05). Secondly, when opinions are examined on general characteristics and the problems of herbal pharmaceutical companies, similar differences are found in case of working period (p<0.01) and in case of total monthly sales amount (p<0.001). Lastly, opinions on the general characteristics and reforms of pharmaceutical companies, similar differences are observed in case of working period (p<0.001). 8. Upon investigating the general characteristics of the improvement of insurance Herbal drugs, the followings are observed. First, regarding general characteristics and insurance benefits, similar differences are observed in case of working period (p<0.05), in case of total monthly sales amount (p<0.05), and in case of average number of daily patients (p<0.01). Secondly, opinions on the general characteristics and the needs for the improvement of Herbal insurance drugs are examined in 5 different aspects, which are the approval of granular type drugs as insurance drugs, the expanded practices of the number of prescription insurance drugs, the needs of a variety of formulations, the needs of TFT of which numbers of Oriental medical doctors are members for the revision of the existing system, and the needs of adjusting the current ceiling of the fixed amount and the fixed rate. When processed by the analysis of variance, the results show similar differences in case of average number of daily patients (p<0.01). Conclusion : From the results of this study the first measures to take are, to reform overall insurance benefit system, including insurance co-payment system(fixed rate cap adjustment), to expand the number of the herbal drugs to be prescribed matching with insurance benefit accordingly, and to revitalize herbal medicine insurance system through the change of various formulations. In addition, it is recommended to improve the effectiveness of herbal medicine by making plans to enhance the efficacy of herbal medicine and by enabling small pharmaceutical companies to outgrow themselves.